The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors.
 
Noboru Yamamoto
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Ono Pharmaceutical; Pfizer; Sysmex
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Navid Hafez
No Relationships to Disclose
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Eleven Biotherapeutics (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Pyxis (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sunshine Guojian (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Vincerx Pharma (Inst); Zentalis (Inst); ZielBio (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Michael Teufel
Employment - Boehringer Ingelheim
 
Junxian Geng
Employment - Boehringer Ingelheim
 
Liz Svensson
Employment - Boehringer Ingelheim
 
Mehdi Lahmar
Employment - Boehringer Ingelheim
 
Mrinal M. Gounder
Honoraria - Flatiron Health; Guidepoint Global; Med Learning Group; Medscape; More Health; PER; PER; touchIME
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics; TYME
Speakers' Bureau - Amgen; Boehringer Ingelheim; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Athenex; Foundation Medicine; Rain Therapeutics